Search Results for: India Globalization
NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Rebrands, Including Changing Name to IGC Pharma, as Part of ‘Major Milestone’ Alignment
India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) will begin operating under the name IGC Pharma Inc. (dba IGC), effective March 30, 2023; the name change is one aspect of the company’s rebranding strategy designed to better reflect its strategic focus and vision for the future. IGC’s common stock will trade on NYSE American exchange … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Rebrands, Including Changing Name to IGC Pharma, as Part of ‘Major Milestone’ Alignment”
NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment
India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment”
India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase
Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://nnw.fm/YNK6P). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE … Continue reading “India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase”
India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms
In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://nnw.fm/2NFz6). The company is developing its proprietary treatment, IGC-AD1, hoping to … Continue reading “India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms”
NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Report, Corporate Update for Q3
India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) is reporting on its financial and corporate performance for the third fiscal quarter 2023. Highlights of the report include a focus on the company’s phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer’s disease. The company reports that the number of sites participating … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Report, Corporate Update for Q3”
NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar
India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday, Feb. 10, Mukunda and Grimaldi will discuss the company’s phase 2 trial for its drug candidate IGC-AD1 in treating agitation … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar”
NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Advances Novel Drug Candidate in Treating Alzheimer’s Symptoms
India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease. “Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Advances Novel Drug Candidate in Treating Alzheimer’s Symptoms”
India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s
In a historic first, India Globalization Capital (NYSE American: IGC) has begun Phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease (https://nnw.fm/Y1rLN). Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment … Continue reading “India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s”
NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Set to Begin IGC-AD1 Phase 2 Trials at Sites Throughout Canada
India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” The letter provides the acknowledgement of IGC-AD1’s drug candidacy … Continue reading “NetworkNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Set to Begin IGC-AD1 Phase 2 Trials at Sites Throughout Canada”
